Skip to main content

Table 2 Univariate analysis of factors affecting RFS of patients with breast cancers of different molecular subtypes

From: KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Clinico-pathological feature Luminal A Luminal B TNBC and basal-like HER2-enriched
p value (HR;CI) p value (HR;CI) p value (HR;CI) p value (HR;CI)
Age (≤ 35, 36–60,> 60 years) 0.934 (0.960; 0.367–2.510) 0.917 (1.059; 0.359–3.129) 0.788 (1.071; 0.651–1.760) 0.099 (0.486; 0.207–1.144)
Nottingham grade 0.062 (2.135; 0.963–4.737) 0.267 (1.763; 0.648–4.798) 0.932 (1.019; 0.658–1.579) 0.382 (1.556; 0.577–4.200)
Tumour size (< 2, 2–5, > 5 cm) 0.202 (1.774; 0.735–4.279) 0.843 (0.901; 0.321–2.529) 0.295 (1.275; 0.809–2.007) 0.054 (1.803; 0.989–3.288)
Lymph node stage 0.021 (1.798; 1.094–2.953) 0.882 (0.964; 0.592–1.570) 0.002 (1.448; 1.148–1.828) 0.003 (1.750; 1.203–2.544)
TNM stage 0.030 (2.441;1.092–5.455) 0.689 (1.174; 0.535–2.573) < 0.001 (2.222; 1.450–3.404) 0.022 (2.034; 1.110–3.727)
Lympho-vascular invasion 0.096 (0.650; 391–1.080) 0.320 (0.756; 0.436–1.312) 0.727 (0.953; 0.726–1.251) 0.819 (0.954; 0.639–1.425)
KIBRA – 4 groups 0.308 (1.304; 0.783–2.173) 0.149 (1.370; 0.894–2.098) 0.983 (0.998; 0.798–1.247) 0.841 (1.034; 0.748–1.429)
Overall KIBRA-low 0.081 (0.384; 0.131–1.125) 0.085 (0.374; 0.122–1.146) 0.422 (0.810; 0.485–1.354) 0.534 (0.775; 0.348–1.728)
Claudin-low 0.005 (0.189; 0.058–0.609) 0.571 (0.684; 0.183–2.552) 0.568 (1.189; 0.656–2.154) 0.699 (1.333; 0.311–5.703)
  1. p significance, ER estrogen expression, PgR progesterone expression, HER2 human epidermal growth factor receptor2, KIBRA-low, low expression of KIBRA in both cytoplasm and nucleus